pharmaphorum5d
FDA approves Adstiladrin as first gene therapy for NMIBC
Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...
The Bakersfield Californian18d
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium
Ferring Pharmaceuticals announced today three abstracts featuring ADSTILADRIN ® (nadofaragene firadenovec-vncg) will be presented at the 2025 American Society of Clinical Oncologists ...